AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities
873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support,...
Great Place To Work Reveals Southeast Asia's Best Workplaces™ in Healthcare & Biopharma
SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honouring 15...
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company....
Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen
CHENGDU, China, Jan. 1, 2026 /PRNewswire/ -- As the Year of the Horse begins, bringing new momentum and promise, Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year. May you stay young,...
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia,...
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium...
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 19, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101,...
See the Future with Luck: VISTA Eye Specialist Promotes Eye Health with CNY Eye Carnival Nationwide
PETALING JAYA, Malaysia, Feb. 14, 2025 /PRNewswire/ -- As people live longer, ensuring a purposeful and fulfilling life becomes even more important. Life expectancy in Malaysia has steadily increased to 76.26 years ([1]), highlighting the growing...
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an...
Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result
Patient advocates call for more support for Australian workers living with a chronic condition/s following the release of a new insights report SYDNEY, Dec. 4, 2024 /PRNewswire/ -- A new report released today has found that of the one in two...